A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Atrasentan; Hormones

Criteria

Inclusion Criteria:

• Diagnosis of prostate cancer.

• Rising PSA while on hormonal therapy or following surgical castration.

• Documented evidence of metastatic disease.

Exclusion Criteria:

• Have received cytotoxic chemotherapy.

• Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.